Receptor tyrosine kinase inhibitors of EGFR or ErbB2 as well as Ang-(1–7) appear to be effective treatments for diabetes-induced vascular dysfunction in animal models [4–5, 7–9, 32]. This evidence concerns the gene EGFR and diabetes mellitus.